US Ophthalmic Topical Therapeutics Market

ID: MRFR/HC/18447-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Ophthalmic Topical Therapeutics Market Research Report: By Product Type (Artificial Tears, Anti-allergy, Antibiotic Drops, Anti-Inflammatory, Antiglaucoma, Others), By Disease Type (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Others), By Dosage Form (Eye Drops, Gels, Ointments, Others) and By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Ophthalmic Topical Therapeutics Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)6.57%
2024 Market Size$ 3.59 Billion
2025 Market Size$ 3.85 Billion
2035 Market Size$ 7.23 Billion

Key Players

Allergan
Bausch + Lomb
Regeneron Pharmaceuticals
Novartis
Santen Pharmaceutical
Aerie Pharmaceuticals
Trends
  • Rise in Personalized Medicine
  • Increased Focus on Combination Therapies
  • Growth of Telemedicine in Eye Care
Opportunities
  • Advancements in Drug Delivery Systems
  • Regulatory Support and Approval Processes
  • Increase in Research and Development Investments
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Anti-inflammatory
      2. 4.1.2 Antibiotic
      3. 4.1.3 Antiviral
      4. 4.1.4 Antiglaucoma
      5. 4.1.5 Lubricants
    2. 4.2 Healthcare, BY Formulation Type (USD Billion)
      1. 4.2.1 Solutions
      2. 4.2.2 Suspensions
      3. 4.2.3 Ointments
      4. 4.2.4 Gels
      5. 4.2.5 Emulsions
    3. 4.3 Healthcare, BY Route of Administration (USD Billion)
      1. 4.3.1 Topical
      2. 4.3.2 Intravitreal
      3. 4.3.3 Subconjunctival
      4. 4.3.4 Periocular
      5. 4.3.5 Systemic
    4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
      1. 4.4.1 Glaucoma
      2. 4.4.2 Dry Eye Disease
      3. 4.4.3 Infectious Diseases
      4. 4.4.4 Allergic Conjunctivitis
      5. 4.4.5 Retinal Disorders
    5. 4.5 Healthcare, BY End User (USD Billion)
      1. 4.5.1 Hospitals
      2. 4.5.2 Ophthalmology Clinics
      3. 4.5.3 Homecare Settings
      4. 4.5.4 Pharmacies
      5. 4.5.5 Research Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Allergan (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bausch + Lomb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Regeneron Pharmaceuticals (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Santen Pharmaceutical (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Aerie Pharmaceuticals (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Horizon Therapeutics (IE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Ocular Therapeutix (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 EyePoint Pharmaceuticals (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY FORMULATION TYPE
    4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
    6. 6.6 US MARKET ANALYSIS BY END USER
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY FORMULATION TYPE, 2026-2035 (USD Billion)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
      4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
      5. 7.2.5 BY END USER, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Ophthalmic Topical Therapeutics Market Segmentation

US Ophthalmic Topical Therapeutics Market By Application (USD Billion, 2026-2035)

  • Anti-inflammatory
  • Antibiotic
  • Antiviral
  • Antiglaucoma
  • Lubricants

US Ophthalmic Topical Therapeutics Market By Formulation Type (USD Billion, 2026-2035)

  • Solutions
  • Suspensions
  • Ointments
  • Gels
  • Emulsions

US Ophthalmic Topical Therapeutics Market By Route of Administration (USD Billion, 2026-2035)

  • Topical
  • Intravitreal
  • Subconjunctival
  • Periocular
  • Systemic

US Ophthalmic Topical Therapeutics Market By Therapeutic Area (USD Billion, 2026-2035)

  • Glaucoma
  • Dry Eye Disease
  • Infectious Diseases
  • Allergic Conjunctivitis
  • Retinal Disorders

US Ophthalmic Topical Therapeutics Market By End User (USD Billion, 2026-2035)

  • Hospitals
  • Ophthalmology Clinics
  • Homecare Settings
  • Pharmacies
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035